TABLE 1.
Baseline characteristics before initiation of crizotinib (n = 61)
| Characteristics | Number (percentage) |
|---|---|
| Gender | |
| Male | 29 (47.5%) |
| Female | 32 (52.5%) |
| Median age | 49 (range 25, 81) |
| <65 | 57 (93.4%) |
| ≥65 | 4 (6.6%) |
| ECOG 0–1 | 50 (82.0%) |
| ECOG ≥2 | 11 (18.0%) |
| Smoking history | |
| Never smoker | 47 ((77.0%) |
| Smoker | 14 (23.0%) |
| Pathology | |
| Adenocarcinoma | 58 (95.1%) |
| Nonadenocarcinoma | 3 (4.9%) |
| Stage | |
| III | 5 (8.2%) |
| IV | 33 (54.1%) |
| Recurrence after surgery | 23 (37.7%) |
| CNS metastases | |
| Yes | 10 (16.4%) |
| No | 51 (83.6%) |
| Distant organs involved | |
| 0 | 8 (13.1%) |
| 1–2 | 44 (72.1%) |
| ≥3 | 9 (14.8%) |
| Target lesions | |
| Yes | 42 (68.8%) |
| No | 19 (31.1%) |
| Variants | |
| Unknown | 33 |
| Non EML4‐ALK fusion | 3 |
| EML4‐V1 | 13 |
| EML4‐V3 | 10 |
| Other EML4 variants | 3 |